Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
ImmuPharma PLC
IMMImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the P140 (Lupuzor), a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140 which is in Phase II for chronic inflammatory demyelinating polyneuropathy, a progressive inflammatory condition of the nerves; and P140 in other indications for asthma, gout, periodontitis, and IBD. Its pre-clinical products include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations for serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection treatment. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom. Address: 1 Bartholomew Close, London, United Kingdom, EC1A 7BL
Analytics
WallStreetin tavoitehinta
387.07 GBXP/E-suhde
–Osinkotuotto
–Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut IMM
Osinkoanalytiikka IMM
Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
–Maksusuhde 5 vuoden keskiarvo
-93 %Osinkohistoria IMM
Osakkeen arvostus IMM
Talousasiat IMM
Tuloksia | 2019 | Dynamiikka |